By a News Reporter-Staff News Editor at Drug Week -- A new study on Immunization and Public Health is now available. According to news originating from Santiago de Compostela, Spain, by NewsRx correspondents, research stated, "Here we report a new nanotechnology-based nasal vaccination concept intended to elicit both, specific humoral and cellular immune responses. The concept relies on the use of a multifunctional antigen nanocarrier consisting of a hydrophobic nanocore, which can allocate lipophilic immunostimulants, and a polymeric corona made of chitosan (CS), intended to associate antigens and facilitate their transport across the nasal mucosa."
Our news journalists obtained a quote from the research from Health Research Institute, "The Toll-like receptor 7 (TLR7) agonist, imiquimod, and the recombinant hepatitis B surface antigen (HB), were selected as model molecules for the validation of the concept. The multifunctional nanocarriers had a nanometric size (around 200 nm), a high positive zeta potential (+45 mV) and a high antigen association efficiency (70%). They also exhibited the ability to enter macrophages in vitro and to effectively deliver the associated imiquimod intracellularly, as noted by the secretion of pro-inflammatory cytokines (i.e. IL-6 and TNF-alpha). However, the nanocarriers did not induce the in vitro activation of the complement cascade. Finally, the positive effect of the co-delivery of HB and imiquimod from the nanocapsules was evidenced upon intranasal administration to mice. The nanocapsules containing imiquimod elicited a protective immune response characterized by increasing IgG levels over time and specific immunological memory."
According to the news editors, the research concluded: "Additionally, the levels of serum IgG subclasses (IgG1 and IgG2a) indicated a balanced cellular/humoral response, thus suggesting the capacity of the nanocapsules to modulate the systemic immune response upon nasal vaccination."
For more information on this research see: Co-delivery of viral proteins and a TLR7 agonist from polysaccharide nanocapsules: A needle-free vaccination strategy. Journal of Controlled Release, 2013;172(3):773-781. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news correspondents report that additional information may be obtained from S. Vicente, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela 15706, Spain. Additional authors for this research include M. Peleteiro, B. Diaz-Freitas, A. Sanchez, A. Gonzalez-Fernandez and M.J. Alonso (see also Immunization and Public Health).
Keywords for this news article include: Spain, Europe, Peptides, Proteins, Amino Acids, Vaccination, Viral Vaccines, Santiago de Compostela, Immunization and Public Health
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC